Xcout Intel
Soleno Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Soleno Therapeutics among biotechnology companies — ranked by similarity to what Soleno Therapeutics actually does, not by market-cap band.
Subscribe to see Soleno Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Soleno Therapeutics
Soleno Therapeutics Inc. is a company based in the United States, focused on the development of therapies. It operates as a Neurocrine Biosciences company, with its headquarters located at 100 Marine Parkway, Suite 400.
Soleno Therapeutics at a glance
Soleno Therapeutics is a biotechnology company headquartered in United States. It has raised at least $75M across the 2 funding rounds on record. Its most recent funding round raised $60M in October 2023.
Soleno Therapeutics funding rounds
At least $75M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $60M | — | |
| SEC Form D filing | $15M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Soleno Therapeutics news
- AcquisitionNeurocrine Biosciences Completes Acquisition of Soleno Therapeutics - PR Newswire
- AcquisitionNeurocrine To Acquire Soleno Therapeutics for $2.9 Bn - DCAT Value Chain Insights
- AcquisitionNeurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PR Newswire
Top 12 Soleno Therapeutics competitors
Ranked by semantic similarity — how close each company is to Soleno Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Neurocrine Biosciences, Inc. is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies for a range of neurological, endocrine, and psychiatric conditions. Its established portfolio offers solutions for conditions such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids. Foremost among its commercialized offerings is INGREZZA, a VMAT2 inhibitor specifically indicated for treating tardive dyskinesia. Other key commercialized therapies include ONGENTYS, a catechol-O-methyltransferase inhibitor functioning as an adjunctive treatment alongside levodopa/DOPA decarboxylase inhibitors for individuals with Parkinson's disease. Additionally, ORILISSA is available for women experiencing moderate to severe endometriosis pain, and ORIAHNN provides an oral, non-surgical option for pre-menopausal women managing heavy menstrual bleeding linked to uterine fibroids. Beyond its marketed drugs, Neurocrine Biosciences maintains a robust pipeline of investigational compounds. This includes NBI-921352, which is being developed to address both pediatric patients and adults with focal epilepsy, and NBI-827104, aimed at rare pediatric epilepsy and essential tremor. Further additions to the clinical development portfolio encompass NBI-1065845 for major depressive disorder (MDD), NBI-1065846 specifically targeting anhedonia within MDD, and NBI-118568, an agent under investigation for schizophrenia. To further its research and development efforts, the company has established strategic alliances and licensing agreements with a notable roster of partners, including Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL – Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Established in 1992, Neurocrine Biosciences, Inc. maintains its headquarters in San Diego, California.
Biotech
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Similar biotechnology company
Solvonis Therapeutics plc is a biopharmaceutical company that develops novel medicines for central nervous system (CNS) disorders. Its initial therapeutic focus is on treating Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with discovery programs extending into broader addiction, psychiatry, and neurology fields.
Similar biotechnology company
Neurogastrx, Inc. is a pharmaceutical manufacturing company founded in 2012. Its main headquarters is located at 500 Unicorn Park Drive in Woburn, Massachusetts, where it is passionate about developing therapies to advance treatment.
Similar biotechnology company
AriBio is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Seongnam, South Korea, with additional offices in the United States. The company focuses on developing novel therapeutics for neurodegenerative diseases.
Biotech
Protagenic Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to the research and development of novel treatments designed to address neuropsychiatric and mood conditions exacerbated by stress. Foremost among its investigational products is PT00114, a laboratory-synthesized version of the teneurin carboxy-terminal associated peptide. This compound functions by emulating an innate brain signaling peptide, known for its ability to temper exaggerated stress reactions. The company's headquarters are located in New York, New York.
Similar biotechnology company
Amygdala Neurosciences Inc is an independent small biopharmaceutical company headquartered in San Francisco, California. Its mission is to invent and develop first-in-class therapeutics.
Similar biotechnology company
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Similar biotechnology company
CuraSen Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies to treat neurodegenerative diseases by targeting specific receptor systems in the brain. The company's scientific approach focuses on restoring neurovascular and neuronal function to serve patients suffering from conditions such as Parkinson's disease and other neurodegenerative disorders.
Biotech
Synendos Therapeutics is a clinical-stage biopharmaceutical and neuroscience company focused on developing a novel class of small molecules to treat psychiatric and neurological disorders.
Similar biotechnology company
Novoron Bioscience, Inc. is a San Diego-based biotechnology company developing novel therapeutics to address central nervous system and other conditions.
Similar biotechnology company
Delix Therapeutics is a privately held biopharmaceutical company headquartered in Boston, Massachusetts, focused on transforming the treatment of brain health through neuroscience.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Soleno Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Soleno Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →